Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) Equity Ratio (2022 - 2025)

Historic Equity Ratio for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to 0.88.

  • Day One Biopharmaceuticals' Equity Ratio fell 508.12% to 0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88, marking a year-over-year decrease of 508.12%. This contributed to the annual value of 0.86 for FY2024, which is 638.78% down from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Equity Ratio stood at 0.88, which was down 508.12% from 0.89 recorded in Q2 2025.
  • Day One Biopharmaceuticals' Equity Ratio's 5-year high stood at 0.97 during Q1 2022, with a 5-year trough of 0.77 in Q2 2024.
  • Moreover, its 4-year median value for Equity Ratio was 0.92 (2024), whereas its average is 0.91.
  • As far as peak fluctuations go, Day One Biopharmaceuticals' Equity Ratio plummeted by 1895.98% in 2024, and later soared by 1591.05% in 2025.
  • Quarter analysis of 4 years shows Day One Biopharmaceuticals' Equity Ratio stood at 0.95 in 2022, then fell by 3.12% to 0.92 in 2023, then dropped by 6.39% to 0.86 in 2024, then increased by 1.73% to 0.88 in 2025.
  • Its last three reported values are 0.88 in Q3 2025, 0.89 for Q2 2025, and 0.9 during Q1 2025.